Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 10/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | IKZF3 | Q9UKT9 | 9/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1398037 | 0.89 | MAP1LC3B (0.40) | CRBNDDB1IKZF3HTR2AHTR2C | |
| SCHEMBL1398096 | 0.89 | CRBN (0.56) | CRBNDDB1IKZF3 | |
| SCHEMBL1398026 | 0.88 | PKM (0.41) | CRBNDDB1IKZF3HTR2AHTR2C | |
| SCHEMBL1398051 | 0.85 | MEN1 (0.40) | CRBNIKZF3HTR2AHTR2CHTR2B | |
| SCHEMBL1398027 | 0.83 | PDE3B (0.42) | CRBNDDB1IKZF3HTR2AHTR2C | |
| SCHEMBL1398061 | 0.81 | PDE3B (0.42) | CRBNDDB1IKZF3PDE3BPDE3A | |
| SCHEMBL1398090 | 0.81 | PDE3B (0.57) | CRBNDDB1IKZF3PDE3BPDE3A | |
| SCHEMBL1398088 | 0.81 | PDE3B (0.40) | CRBNDDB1IKZF3PDE3BPDE3A | |
| SCHEMBL1398077 | 0.81 | CRBN (0.48) | CRBNDDB1IKZF3PDE3BPDE3A | |
| SCHEMBL1398060 | 0.81 | PDE3B (0.37) | CRBNDDB1IKZF3PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957481-B1 | PYRROLIDIN(THI)ONES HETEROCYCLICALLY SUBSTITUTED IN 3-POSITION | GRUENENTHAL GMBH (DE) | 2011-03-02 | — | — | EP | claimed |
| US-20080293749-A1 | Pyrrolidine(thi)ones Substituted by Heterocyclic Substituents in The 3-Position | GRUENENTHAL GMBH (DE) | 2008-11-27 | — | — | US | claimed |
| EP-1957481-B1 | PYRROLIDIN(THI)ONES HETEROCYCLICALLY SUBSTITUTED IN 3-POSITION | GRUENENTHAL GMBH (DE) | 2011-03-02 | — | — | EP | disclosed |
| US-20080293749-A1 | Pyrrolidine(thi)ones Substituted by Heterocyclic Substituents in The 3-Position | GRUENENTHAL GMBH (DE) | 2008-11-27 | — | — | US | disclosed |
| EP-1957481-A1 | PYRROLIDIN(THI)ONES HETEROCYCLICALLY SUBSTITUTED IN 3-POSITION | Grünenthal GmbH (DE) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007062817-A1 | PYRROLIDIN(THI)ONES HETEROCYCLICALLY SUBSTITUTED IN 3-POSITION | Grünenthal GmbH (DE) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293749-A1 | Pyrrolidine(thi)ones Substituted by Heterocyclic Substituents in The 3-Position | TPMT, MALT1, THPO | CRBN 1317/4885DDB1 1517/4885IKZF3 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.